<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02923960</url>
  </required_header>
  <id_info>
    <org_study_id>BL33</org_study_id>
    <nct_id>NCT02923960</nct_id>
  </id_info>
  <brief_title>Effect of Nutritional Products in Subjects With Type 2 Diabetes</brief_title>
  <official_title>Effect of Nutritional Products on Metabolic Parameters in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Nutrition</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Nutrition</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blinded, multi treatment, crossover study intended to compare
      the glycemic and insulinemic response after consuming liquid nutritional products in people
      with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Glucose Concentration</measure>
    <time_frame>0 to 240 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Insulin Concentration</measure>
    <time_frame>0 to 240 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Standard ONS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>liquid oral nutritional supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes specific ONS 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>liquid oral nutritional supplement with novel carbohydrate blend</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes specific ONS 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>liquid oral nutritional supplement with novel carbohydrate blend</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard ONS</intervention_name>
    <description>One serving (237 ml) standard oral nutritional beverage</description>
    <arm_group_label>Standard ONS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diabetes specific ONS 1</intervention_name>
    <description>One serving (237 ml) diabetes oral nutritional beverage</description>
    <arm_group_label>Diabetes specific ONS 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diabetes specific ONS 2</intervention_name>
    <description>One serving (296 ml) diabetes oral nutritional beverage</description>
    <arm_group_label>Diabetes specific ONS 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has type 2 diabetes

          -  Subject is a male or a nonpregnant, nonlactating female, at least 6 weeks postpartum
             prior to screening visit

          -  Subject's BMI is &gt; 18.5 kg/m2 and &lt; 35 kg/m2

          -  If on a chronic medication such as antihypertensive, lipid lowering, thyroid
             medication or hormone therapy, subject has been on constant dosage for at least two
             months prior to screening visit

          -  Subject states willingness to follow protocol as described, including consumption of
             study product per protocol and completing any required study forms

          -  Participant must refrain from taking medications/dietary supplements/herbals or
             substances that could modulate glucose metabolism (other than oral hypoglycemic
             medications), or considered anabolic, or reduce weight (fat mass)

        Exclusion Criteria:

          -  Subject is currently diagnosed with, or has a history of severe dementia or delirium,
             eating disorder, history of significant neurological or psychiatric disorder,
             alcoholism, substance abuse or other conditions that may interfere with study product
             consumption or compliance with study protocol procedures

          -  Subject is known to be allergic or intolerant to any ingredient found in the study
             products

          -  Subject is participating in another study that has not been approved as a concomitant
             study

          -  Subject uses exogenous insulin for glucose control, or subject states that they have
             been diagnosed as having Type 1 diabetes

          -  Subject states they have a history of diabetic ketoacidosis

          -  Subject is currently on a low carbohydrate or very low carbohydrate diet

          -  Subject states that he/she has a current infection; has had inpatient surgery, or
             corticosteroid treatment in the last 3 months or antibiotics in the last 3 weeks prior
             to screening visit

          -  Subject states that he/she has an active malignancy

          -  Subject states that he/she has had a significant cardiovascular event ≤ six months
             prior to screening visit; or stated history of congestive heart failure

          -  Subject states that he/she has end stage organ failure or is status post organ
             transplant

          -  Subject is diagnosed with chronic kidney disease, or a history of kidney issues

          -  Subject states they have impaired liver function, or have a history of liver disease

          -  Subject has an obstruction of the gastrointestinal tract precluding ingestion of the
             study product, inflammatory bowel disease, short bowel syndrome or other severe forms
             of gastrointestinal disease such as gastroesophageal reflux disease, gastroparesis,
             peptic ulcer disease, celiac disease, intestinal dysmotility, diverticulitis, or
             ischemic colitis, or any other related condition that may cause unnecessary subject
             discomfort

          -  Subject states they have a chronic, contagious, infectious disease

          -  Subject has taken/is currently taking any herbals, dietary supplements, or medications
             during the past four weeks prior to screening visit that are designed to affect blood
             glucose.

          -  Subject states that he/she has clotting or bleeding disorders

          -  If selected for continuous blood glucose monitoring, subject has skin lesions,
             hyperhidrosis, eczema, psoriasis, scarring, redness, infection or edema at the flash
             constant glucose monitoring application site(s) that could interfere with device
             placement or the accuracy of interstitial glucose measurements.

          -  If selected for continuous blood glucose monitoring, subject has an X-ray, MRI or CT
             appointment scheduled during the period of study participation, or another procedure
             that would require removal of the flash constant glucose monitoring sensor.

          -  Subjects on sulfonylureas, meglitinides, and α-glucosidase inhibitors, insulin, or
             subject on more than two oral hypoglycemic medications excluding aforementioned.

          -  Subjects on oral hypoglycemic medications that has changed in last 2 months.

          -  Subject's HbA1c, per point of care device is &gt; 8%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Owen Kelly, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott Nutrition</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Great Lakes Clinical Trials</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2016</study_first_posted>
  <last_update_submitted>April 14, 2017</last_update_submitted>
  <last_update_submitted_qc>April 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

